Business Context and Reporting Period
The Chemours Company filed a Form 8-K on September 25, 2015, reporting the entry into a material definitive agreement. The filing details Amendment No. 1 to the Company's Credit Agreement dated May 12, 2015, with JPMorgan Chase Bank, N.A., as administrative agent.
Key Financial Metrics and Covenant Adjustments
The filing does not report current revenue, profit, cash flow, or debt balances. Instead, it outlines specific adjustments to financial covenants and dividend baskets within the Credit Agreement:
- Consolidated EBITDA Definition: Modified to include pro forma cost savings benefits from restructuring initiatives announced prior to July 1, 2016.
- EBITDA Add-back Limits: $115 million for any four fiscal quarter period ending on or prior to June 30, 2016; $80 million for periods ending after June 30, 2016.
- Fixed Dollar Annual Dividend Basket: Adjusted to $106 million for the fiscal year ended December 31, 2015, and $22 million per annum for fiscal years ending December 31, 2016, and December 31, 2017.
Material Changes and Strategic Intent
The primary material change is the amendment to the Credit Agreement designed to provide enhanced liquidity to implement the Company's transformation plan and strengthen its financial position. The modification of the EBITDA definition allows the Company to account for specific restructuring cost savings when calculating financial maintenance covenants.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the Company's transformation plans, resolution of environmental liabilities, litigation, and target leverage. Management notes that actual results may differ materially due to substantial risks and uncertainties. The Company explicitly states it undertakes no duty to update these forward-looking statements. No specific guidance on future revenue or earnings is provided in this document.
Key Facts for Investor Verification
- Verify the full text of Amendment No. 1 attached as Exhibit 10.1 to understand all covenant terms.
- Monitor the Company's ability to achieve the restructuring cost savings required to utilize the EBITDA add-backs.
- Review the Company's cash flow projections to ensure compliance with the adjusted dividend basket limits.
- Assess the status of environmental liabilities and litigation mentioned as key risk factors in other filings.